Medisyn Technologies developed computational chemistry platforms and proprietary molecular topology software for pharmaceutical drug discovery and development. The company's Forward Engineering platform applied advanced mathematical modeling to analyze the atomic connectivity of chemical structures, predicting biological activity without traditional high-throughput screening. Its computational systems identified and optimized targeted bioactive compounds for research partners across multiple therapeutic areas.
The company established collaborative research agreements with commercial partners including Kraft Foods alongside academic institutions to engineer novel therapeutic and functional compounds. In December 2016, Medisyn Technologies officially ceased operations and dissolved after concluding its proprietary drug discovery initiatives and computational development operations.
